LXEO Quote, Financials, Valuation and Earnings

bluebird bio has a net margin of -- compared to Lexeo Therapeutics's net margin of -75.09%. Lexeo Therapeutics's return on equity of -- beat bluebird bio's return on equity of -1125.51%.

Lexeo Therapeutics has a consensus price target of $18.57, signalling upside risk potential of 577.79%. On the other hand bluebird bio has an analysts' consensus of $8.00 which suggests that it could grow by 60.64%. Given that Lexeo Therapeutics has higher upside potential than bluebird bio, analysts believe Lexeo Therapeutics is more attractive than bluebird bio.

Lexeo Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison bluebird bio has a beta of 0.292, suggesting its less volatile than the S&P 500 by 70.839%.

Lexeo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. bluebird bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics pays -- of its earnings as a dividend. bluebird bio pays out -- of its earnings as a dividend.

Lexeo Therapeutics quarterly revenues are --, which are smaller than bluebird bio quarterly revenues of $38.7M. Lexeo Therapeutics's net income of -$32.7M is lower than bluebird bio's net income of -$29.1M. Notably, Lexeo Therapeutics's price-to-earnings ratio is -- while bluebird bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics is -- versus 0.47x for bluebird bio. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Lexeo Therapeutics's net margin of --. Lexeo Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Lexeo Therapeutics has a consensus price target of $18.57, signalling upside risk potential of 577.79%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 435.71%. Given that Lexeo Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Lexeo Therapeutics is more attractive than Perspective Therapeutics.

Lexeo Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Lexeo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Lexeo Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Lexeo Therapeutics's net income of -$32.7M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Lexeo Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics is -- versus 18.18x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics has a net margin of -- compared to Lexeo Therapeutics's net margin of 13.07%. Lexeo Therapeutics's return on equity of -- beat Corcept Therapeutics's return on equity of 21.3%.

Lexeo Therapeutics has a consensus price target of $18.57, signalling upside risk potential of 577.79%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 78.04%. Given that Lexeo Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Lexeo Therapeutics is more attractive than Corcept Therapeutics.

Lexeo Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.473%.

Lexeo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Lexeo Therapeutics quarterly revenues are --, which are smaller than Corcept Therapeutics quarterly revenues of $157.2M. Lexeo Therapeutics's net income of -$32.7M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Lexeo Therapeutics's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 66.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics is -- versus 13.14x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CervoMed has a net margin of -- compared to Lexeo Therapeutics's net margin of --. Lexeo Therapeutics's return on equity of -- beat CervoMed's return on equity of --.

Lexeo Therapeutics has a consensus price target of $18.57, signalling upside risk potential of 577.79%. On the other hand CervoMed has an analysts' consensus of $15.83 which suggests that it could grow by 101.19%. Given that Lexeo Therapeutics has higher upside potential than CervoMed, analysts believe Lexeo Therapeutics is more attractive than CervoMed.

Lexeo Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CervoMed has a beta of -0.229, suggesting its less volatile than the S&P 500 by 122.909%.

Lexeo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CervoMed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics pays -- of its earnings as a dividend. CervoMed pays out -- of its earnings as a dividend.

Lexeo Therapeutics quarterly revenues are --, which are smaller than CervoMed quarterly revenues of --. Lexeo Therapeutics's net income of -$32.7M is lower than CervoMed's net income of -$4.9M. Notably, Lexeo Therapeutics's price-to-earnings ratio is -- while CervoMed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics is -- versus 110.11x for CervoMed. Usually stocks with elevated PS ratios are considered overvalued.